Draft Guidance for Industry, Clinical Laboratories, and FDA Staff: In Vitro Diagnostic Multivariate Index Assays

No abstract is available for this paper.

• Publication year

  2007

• Venue

  Biotechnology Law Report

• Publication date

  2007-04-01

• Fields of study

  Not labeled

• Identifiers
  DOI 10.1089/blr.2006.9979
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar

• No claims are published for this paper.

• No concepts are published for this paper.

• No references are available for this paper.

• What Every Clinical Virologist Should Know About The VALID Act On Behalf of the Pan-American Society for Clinical Virology Clinical Practice Com.

  2021cites this paper
• The Case For

  2018cites this paper
• Best serum biomarker combination for ovarian cancer classification

  2018cites this paper
• Validation of biomarkers to predict response to immunotherapy in cancer: Volume II — clinical validation and regulatory considerations

  2016cites this paper
• Identification of Mycobacterial Antigens in Human Urine by Use of Immunoglobulin G Isolated from Sera of Patients with Active Pulmonary Tuberculosis

  2016cites this paper
• Challenges and opportunities for translating medical microdevices: insights from the programmable bio-nano-chip.

  2016cites this paper
• Targeted therapies with companion diagnostics in the management of breast cancer: current perspectives

  2016cites this paper
• The future of laboratory medicine - a 2014 perspective.

  2015cites this paper
• SOCIO-ETHICAL ISSUES IN PERSONALIZED MEDICINE: A SYSTEMATIC REVIEW OF ENGLISH LANGUAGE HEALTH TECHNOLOGY ASSESSMENTS OF GENE EXPRESSION PROFILING TESTS FOR BREAST CANCER PROGNOSIS

  2015cites this paper
• Performance Evaluation of the ARCHITECT HE4 Assay

  2014cites this paper
• A multi-marker molecular signature approach for treatment-specific subgroup identification with survival outcomes

  2014cites this paper
• Intellectual property and regulation of molecular pathology tests.

  2014cites this paper
• A Call for Participatory Oversight

  2014cites this paper
• Regulation of Clinical Tests: In Vitro Diagnostic (IVD) Devices, Laboratory Developed Tests (LDTs), and Genetic Tests

  2014cites this paper
• Genomic Medicine: A Decade of Successes, Challenges, and Opportunities

  2013cites this paper
• Criteria for the use of omics-based predictors in clinical trials: explanation and elaboration

  2013cites this paper
• Practical Guidance for Implementing Predictive Biomarkers into Early Phase Clinical Studies

  2013cites this paper
• The long journey of cancer biomarkers from the bench to the clinic.

  2013cites this paper
• Clinical Biomarkers in Oncology Focus on Colorectal Cancer

  2012cites this paper
• Bridging the "Valley of Death" in stratified medicine : commercializing molecular diagnostics in oncology

  2012cites this paper
• Genomic Classifier for Patient Enrichment: Misclassification and Type I Error Issues in Pharmacogenomics Noninferiority Trial

  2011cites this paper
• The Path to Clinical Proteomics Research: Integration of Proteomics, Genomics, Clinical Laboratory and Regulatory Science

  2011cites this paper
• Quality Assurance and Quality Improvement in U.S. Clinical Molecular Genetic Laboratories

  2011cites this paper
• Diagnostic Testing for Vaccinomics: Is the Regulatory Approval Framework Adequate? A Comparison of Canada, the United States, and Europe

  2011cites this paper
• What information should be required to support clinical "omics" publications?

  2011cites this paper
• Implementing genotype-guided antithrombotic therapy.

  2010cites this paper
• The future of diagnostic gene-expression microarrays: bridging the gap between bench and bedside.

  2010cites this paper
• FDA and CLIA Oversight of Advanced Diagnostics and Biomarker Tests

  2010cites this paper
• Evaluating diagnostic accuracy of genetic profiles in affected offspring families

  2010cites this paper
• Translating Innovation in Diagnostics: Challenges and Opportunities

  2009influential citation
• Economic potential for clinically significant in vitro diagnostics

  2009cites this paper
• Personalized medicine and disruptive innovation: Implications for technology assessment

  2009cites this paper
• The Evaluation of Genomic Applications in Practice and Prevention (EGAPP) initiative: methods of the EGAPP Working Group

  2009cites this paper
• Molecular Diagnostics

  2009cites this paper
• Developing the Blueprint for a Genetic Testing Registry

  2009cites this paper
• Genomic signatures of cancer progression: from in vitro experimental models to prediction of human breast cancer outcome.

  2008cites this paper
• The current status and future potential of personalized diagnostics: Streamlining a customized process.

  2008cites this paper
• Genomics in Drug Discovery and Development

  2008cites this paper
• Biomarker Development, Commercialization, and Regulation: Individualization of Medicine Lost in Translation

  2007cites this paper
• Molecular Medicine: How, What, and When?

  2007cites this paper
• ASHG Statement* on Direct-to-Consumer Genetic Testing in the United States

  2007cites this paper
• ORGANIZATIONAL REPUTATION AND THE TIMING OF AGENCY EXPANSION: AN ANALYSIS OF FDA'S RESPONSE TO THE EMERGENCE OF INNOVATIVE MEDICAL TECHNOLOGIES

  2007cites this paper
• Challenges in DNA Microarray Studies from the Regulatory Perspective

  2007cites this paper